《大行報告》大和升九興(01836.HK)評級至「買入」 目標價上調至12.3元
大和發表研究報告指,九興控股(01836.HK)上半年錄得盈利3,220萬美元,撇除一次性支出後經調整淨利潤達3,700萬美元,一如預期公司重新宣派中期股息,派息比率達70%,稍低於疫情前水平。
報告指出,管理層終於再次上調全年出貨量指引至按年增長25%至30%,高於該行及市場預期。大和相信,隨著公司銷售表現復甦,市場份額回升,毛利率亦會有所恢復,預測明年九興出貨量將創新高達到6,030萬。
大和將2021至2023年收入預測上調7%至10%,在研發開支增加下,上調每股核心盈利預測僅約2%,並將目標價由12元上調至12.3元,評級由「跑贏大市」提升至「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.